Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nat Rev Urol. 2020 Sep;17(9):491-492. doi: 10.1038/s41585-020-0357-1.
Anti-PD1 and anti-PDL1 immunotherapy has transformed urothelial carcinoma treatment. Pembrolizumab is the only immunotherapy agent shown to have survival benefit compared with standard chemotherapy after progression on platinum-containing chemotherapy. Initial National Institute for Health and Care Excellence (NICE) approval was based on efficacy data, but the final appraisal report rejected use of pembrolizumab owing to treatment cost.
抗 PD1 和抗 PDL1 免疫疗法改变了尿路上皮癌的治疗方式。与含铂化疗进展后的标准化疗相比，帕博利珠单抗是唯一显示有生存获益的免疫治疗药物。最初的英国国家卫生与临床优化研究所（NICE）的批准是基于疗效数据，但最终的评估报告因治疗费用而拒绝使用帕博利珠单抗。
